Lam Research Corporation vs DENTSPLY SIRONA Inc — how do they compare? Lam Research Corporation trades at $318.84 (market cap $401.19B), while DENTSPLY SIRONA Inc trades at $8.83 (market cap $1.73B). The key difference: Lam Research Corporation is far larger — about 231.9× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals — on Pluang, investors hold Lam Research Corporation for 60 Days and DENTSPLY SIRONA Inc for 72 Days on average.
| LRCX | XRAY | |
|---|---|---|
Market Cap | $401.19B | $1.73B |
Volume | 8,960,892 | 6,198,582 |
Sector | Technology | Health |
52-Week High | $433.33 | $14.68 |
52-Week Low | $131.37 | $8.52 |
Typical Hold Time | 60 Days | 72 Days |
Enterprise Value | $399.35B | $3.80B |
Dividend Yield | 0.41% | 5.04% |
Signals from Pluang's Aura AI — not financial advice
Lam Research (LRCX) trades at $320.59, down 2.71% on the day, with a bearish technical signal but strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $2.18. Revenue grew to $18.44B in 2025, with a net income margin of 31.27%, while valuation ratios like P/E of 55.66 and P/S of 17.4 reflect high growth expectations. Analyst consensus is strongly bullish with a $375.68 price target, supported by AI-driven demand for semiconductor equipment.
The outlook for LRCX is positive due to robust earnings growth and strategic positioning in AI infrastructure, though risks include high valuation multiples and semiconductor cycle volatility. Upside potential exists if the company meets Q3 2026 earnings expectations and maintains margin expansion, but investors should monitor competitive pressures and macroeconomic factors affecting tech spending.
DENTSPLY SIRONA (XRAY) trades at $8.69, near its 52-week low, with a bearish technical signal from moving averages. The company reported a Q2 2026 earnings beat but faces declining revenue and negative net income margins. Recent news highlights institutional stake increases and ongoing restructuring efforts amid weak dental market conditions.
The outlook remains challenging with persistent profitability issues and high debt levels, though analyst consensus suggests upside potential with a $13 price target. Key risks include margin pressure and competitive threats, requiring careful monitoring of the company's turnaround execution for any recovery signs.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Lam Research manufactures equipment used to fabricate semiconductors. The firm is focused on the etching, deposition, and clean markets, which are key steps in the semiconductor manufacturing process, especially for 3D NAND flash storage, advanced DRAM, and leading-edge logic/foundry chipmakers. Lam's flagship Kiyo, Vector, and Sabre products are sold in all major geographies to key customers such as Samsung Electronics, Micron, Intel, and Taiwan Semiconductor Manufacturing.
Read more on LRCX →Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →